RSS-Feed abonnieren
DOI: 10.1055/s-0032-1323805
Comprehensive Genetic Analysis and Structural Characterization of CYP21A2 Mutations in CAH Patients
Publikationsverlauf
received 12. Dezember 2011
first decision 11. Juli 2012
accepted 24. August 2012
Publikationsdatum:
16. Oktober 2012 (online)
![](https://www.thieme-connect.de/media/eced/201209/lookinside/thumbnails/10.1055-s-0032-1323805-1.jpg)
Abstract
Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency is a common autosomal recessive disorder caused by mutations in the steroid 21-hydroxylase gene (CYP21A2). Complete DNA sequencing of CYP21A2 was performed in 5 patients, 3 non-classic and 2 classic forms of the disease, that were previously screened for the 10 most common mutations, in order to detect additional mutations that could justify the phenotype of the patients. 5 mutations were identified with the whole gene extended analysis. The mutations, p.Pro432Leu and p.Ala434Glu, the first previously reported by our group and the second a novel one were structurally analyzed with ICM-Pro software regarding biochemical properties such as protein stability, accessibility to surface and hydrophobicity, in order to elucidate their effects on the CYP21A2 protein. The 2 affected residues, Pro432 and Ala434, were also studied for conservation purposes in order to predict the severity of both mutations with PolyPhen-2 software and were considered as “probably damaging”. Prediction of clinical severity, based on molecular modelling and sequence conservation, was in accordance with the patient’s clinical diagnosis.
-
References
- 1 Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249
- 2 Bachelot A, Chakthoura Z, Rouxel A et al. Classical forms of Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008; 69: 203-211
- 3 Barbaro M, Baldazzi L, Balsamo A et al. Functional studies of two novel and two rare mutations in the 21-hydroxylase gene. J Mol Med 2006; 84: 521-528
- 4 Carvalho B, Marques CJ, Carvalho D et al. Novel human pathological mutations. Gene symbol: CYP21A2. Disease: adrenal hyperplasia. Hum Genet 2010; 127 (04) 482-483
- 5 Chenna R, Sugawara H, Koike T et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003; 31: 3497-3500
- 6 European Bioinformatics Institute UK, accessed on the 2010/01/14, at http://www.ebi.ac.uk/333
- 7 Friães A, Rêgo AT, Aragüés JM et al. CYP21A2 mutations in Portuguese patients with congenital adrenal hyperplasia: identification of two novel mutations and characterization of four different partial gene conversions. Mol Genet Metab 2006; 88: 58-65
- 8 Gonçalves J, Friães A, Moura L. Congenital adrenal hyperplasia: focus on the molecular basis of 21-hydroxylase deficiency. Expert Rev Mol Med 2007; 9: 1-23
- 9 Huynh T, McGown I, Cowley D et al. The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency. Clin Biochem Rev 2009; 30: 75-86
- 10 Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-132
- 11 Lee HH, Chang JG, Tsai CH et al. Analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. Clin Chem 2000; 46: 606-611
- 12 Loidi L, Quinteiro C, Parajes S et al. High variability in CYP21A2 mutated alleles in Spanish 21-hydroxylase deficiency patients, six novel mutations and a founder effect. Clin Endocrinol 2006; 64: 330-336
- 13 Marques CJ, Pignatelli D, Carvalho B et al. Mutational characterization of steroid 21-hydroxylase gene in Portuguese patients with congenital adrenal hyperplasia. Exp Clin Endocrinol Diabetes 2010; 118: 505-512
- 14 Mount SM. A catalogue of splice junction sequences. Nucleic Acids Res 1982; 10: 459-472
- 15 Nieman LK. Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency. UpToDate 19.2. Accessed on the 2011/11/10, at http://www.uptodate.com/contents/diagnosis-and-treatment-of-nonclassic-late-onset-congenital-adrenal-hyperplasia-due-to-21-hydroxylase-deficiency#H2
- 16 Ogino S, Gulley ML, den Dunnen JT et al. and the Association for Molecular Pathology Training and Education Committee . Standard mutation nomenclature in molecular diagnostics. Practical and educational challenges. J Mol Diagn 2007; 9: 1-6
- 17 Protein Data Bank-RCSB accessed on the 2010/12/10, at http://www.rcsb.org/pdb
- 18 Robins T, Carlsson J, Sunnerhagen M et al. Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia. Mol Endocrinol 2006; 20: 2946-2964
- 19 Rodrigues NR, Dunham I, Yu CY et al. Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J 1987; 6: 1653-1661
- 20 Speiser PW, Dupont J, Zhu D et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90: 584-595
- 21 Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788
- 22 Stenson PD, Mort M, Ball EV et al. The Human Gene Mutation Database (HGMD®): 2008 Update. Genome Med 2009; 1 (01) 13
- 23 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291
- 24 White PC, Vitek A, Dupont B et al. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988; 85: 4436-4440